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INTRODUCTION
Chronic obstructive pulmonary disease 
(COPD) affects around 2% of the UK 
population, and is the third leading cause 
of death globally.1–3 More than 70% of 
patients presenting with acute exacerbations 
of COPD (AECOPD) in primary care are 
prescribed an antibiotic,4 despite bacterial 
pathogens only being detectable in 20%–
50% of exacerbations.5–7 Antibiotic use for 
AECOPD accounts for 7.5% of all primary 
care antibiotic prescriptions.8
Overuse of antibiotics contributes to the 
development of antimicrobial resistance, 
exposes patients to the risk of unnecessary 
side effects, wastes money, and undermines 
self-care.9 There is, therefore, a need for 
antimicrobial stewardship initiatives to target 
the prescribing of antibiotics for patients with 
AECOPD in primary care.
The PACE trial demonstrated that a 
management strategy involving the use of 
C-reactive protein (CRP) point-of-care testing 
(POCT) for patients with AECOPD in primary 
care can lead to a reduction in antibiotic use 
without any evidence of patient harm.10 In this 
randomised controlled trial, antibiotics were 
used by 77% of patients in the usual-care 
group compared with 57% in the CRP-POCT 
group (a relative difference of 26%), while 
potential bacterial pathogens were isolated 
in the sputum of only 44% of participants. 
This suggests that there may be potential for 
further reductions in antibiotic prescribing, 
and it is therefore important to understand 
the determinants of antibiotic prescribing for 
this condition.
The aim of this study was to examine 
the presenting features associated with 
antibiotic prescribing decisions for AECOPD 
Abstract
Background
C-reactive protein (CRP) point-of-care testing 
can reduce antibiotic use in patients with acute 
exacerbation of chronic obstructive pulmonary 
disease (AECOPD) in primary care, without 
compromising patient care. Further safe 
reductions may be possible.
Aim
To investigate the associations between 
presenting features and antibiotic prescribing in 
patients with AECOPD in primary care.
Design and setting
Secondary analysis of a randomised controlled 
trial of participants presenting with AECOPD in 
primary care (the PACE trial). 
Method
Clinicians collected participants’ demographic 
features, comorbid illnesses, clinical signs, and 
symptoms. Antibiotic prescribing decisions were 
made after participants were randomised to 
receive a point-of-care CRP measurement or 
usual care. Multivariable regression models were 
fitted to explore the association between patient 
and clinical features and antibiotic prescribing, 
and extended to further explore any interactions 
with CRP measurement category (CRP not 
measured, CRP <20 mg/l, or CRP ≥20 mg/l).
Results
A total of 649 participants from 86 general 
practices across England and Wales were 
included. Odds of antibiotic prescribing were 
higher in the presence of clinician-recorded 
crackles (adjusted odds ratio [AOR] = 5.22, 95% 
confidence interval [CI] = 3.24 to 8.41), wheeze 
(AOR = 1.64, 95% CI = 1.07 to 2.52), diminished 
vesicular breathing (AOR = 2.95, 95% CI = 1.70 
to 5.10), or clinician-reported evidence of 
consolidation (AOR = 34.40, 95% CI = 2.84 to 
417.27). Increased age was associated with lower 
odds of antibiotic prescribing (AOR per additional 
year increase = 0.98, 95% CI = 0.95 to 1.00), as was 
the presence of heart failure (AOR = 0.32, 95% 
CI = 0.12 to 0.85).
Conclusion
Several demographic features and clinical signs 
and symptoms are associated with antibiotic 
prescribing in AECOPD. Diagnostic and prognostic 
value of these features may help identify further 
safe reductions.
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in primary care, and to explore if these were 
different when clinicians had access to a 
CRP measurement (available for patients 
randomised to the intervention arm of 
the trial), and whether the CRP value was 
elevated (≥20 mg/l) or not.
METHOD
Study design
This was a secondary analysis of an open, 
multi-site, parallel-group, individually 
randomised controlled trial that evaluated the 
effectiveness of a CRP-POCT management 
strategy for patients with an AECOPD in 
UK primary care (the PACE trial). Target 
recruitment was 650 participants. The 
protocol and findings for the original study 
are reported elsewhere.10–12 
Participants and setting
Participants aged ≥40 years with a clinically 
recorded diagnosis of COPD (with or without 
spirometry confirmation) who presented with 
an acute exacerbation for 1–21 days were 
recruited into the trial from general practices 
across England and Wales. Full inclusion 
and exclusion criteria have been described 
previously.11 
Procedures
After patients gave informed consent, their 
baseline data were collected. Participants 
were then randomly allocated using remote 
online computer randomisation (ratio 1:1) 
either to management via usual care (no 
CRP-POCT) or to CRP-POCT in addition to 
usual care. 
All general practices (n = 86) were provided 
with a POCT device and all associated 
materials, information on current best 
practice for managing AECOPD, with no 
other specific guidance given to clinicians 
with regards to the management of their 
patients. Participants allocated to the usual-
care arm were managed without the use 
of a CRP-POCT measurement. Those 
allocated to the CRP-POCT arm had a CRP 
measurement taken using a POCT desktop 
machine, to help guide initial antibiotic 
prescribing decisions. Clinicians received 
guidance and training on how to use the 
device and interpret the result. The guidance 
indicated that antibiotics were unlikely to 
be beneficial and should usually not be 
prescribed for patients with a CRP <20 mg/l; 
that antibiotics may be beneficial, especially 
if purulent sputum is present, for patients 
with a CRP 20–40 mg/l; and that antibiotics 
are likely to be beneficial and should usually 
be prescribed (unless a patient is assessed 
as being at low risk of complications) for 
patients with a CRP >40 mg/l. The CRP 
cut-offs were based on data from a placebo-
controlled trial of antibiotics for patients with 
acute exacerbations of mild-to-moderate 
COPD.13 
Clinicians recorded participants’ 
demographic details (age and sex), their 
medical history (presence of comorbidities 
and COPD stage according to Global Initiative 
for Chronic Obstructive Lung Disease [GOLD] 
criteria), and clinical features pertaining 
to their exacerbation: number of days 
experiencing symptoms, temperature, pulse 
rate, oxygen saturation, ability to complete 
a full sentence, tachypnoea, presence 
and number of Anthonisen symptoms 
(increased shortness of breath, increased 
sputum volume, and/or increased sputum 
purulence),14 presence of crackles, wheeze, 
diminished vesicular sounds, or evidence of 
consolidation on auscultation of the lungs. 
Clinicians recorded the colour of the sputum 
sample using a BronkoTest chart.15 Where 
a sputum sample could not be obtained, 
participants estimated their current sputum 
colour using the chart. Participants were 
also asked about their smoking status (non-
smoker, current smoker, or ex-smoker) 
during 1-week follow-up assessments. 
Antibiotic prescribing and other 
management decisions were made and 
recorded after receipt of the test result for 
those allocated to the CRP-POCT arm.
Statistical methods
Descriptive statistics were reported as 
frequencies and percentages or means and 
standard deviations, as appropriate.
How this fits in 
Overuse of antibiotics contributes to 
antimicrobial resistance, unnecessarily 
exposes patients to side effects, 
and undermines self-care. A recent 
randomised controlled trial demonstrated 
that, when clinical management is 
supplemented with a C-reactive protein 
(CRP) point-of-care test, antibiotics can 
be safely reduced in patients presenting in 
primary care with an acute exacerbation 
of chronic obstructive pulmonary disease 
(AECOPD). Further analysis, in the present 
study, found several demographic and 
clinical features associated with the 
prescribing of antibiotics to patients 
presenting with AECOPD in UK primary 
care, independent of the CRP test result. 
Studying the diagnostic and prognostic 
value of these features is warranted to 
understand how to safely reduce antibiotic 
use in this population.
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To investigate the association between 
patient and clinical features and antibiotic 
prescribing, multilevel multivariable logistic 
regression models were fitted, accounting 
for any clustering of participants in practices. 
Each explanatory variable (those described 
in the Procedures section) was included 
in separate regression models. Sputum 
colour was ranked 1 (lightest colour) to 
5 (darkest colour). Continuous variables 
were grand-mean-centred and included 
as linear effects following the inspection of 
model parsimony, when comparing linear 
terms with restricted cubic splines with 
both five and three knots, using the Akaike 
information criterion (see Supplementary 
Table S1 for details). Each model was 
adjusted for CRP measurement (defined 
as no measurement taken, CRP <20 mg/l, 
and CRP ≥20 mg/l) in addition to increased 
sputum purulence. Sputum purulence was 
adjusted for as a potential confounder as 
it was an exacerbation feature specifically 
mentioned in the guidance on interpreting 
the CRP measurement. The differential 
association between explanatory variables 
and antibiotic prescribing by CRP 
measurement was explored by extending 
models to include CRP measurement 
interacted with explanatory variables.
The proportion of the total variance, for 
explanatory variable, that was attributable to 
differences across practices was expressed 
by estimating the intra-cluster correlation 
coefficient (ICC), with the π2/3 estimator 
used where considering a binary response. 
These were calculated to indicate practice 
(as a proxy for prescriber) variation in the 
reporting of these features.




The PACE trial consented and randomised 
653 participants from 86 general practices 
across England and Wales. Three participants 
withdrew their permission for their data to 
be used and one was randomised in error, 
leaving 649 participants: 324 were allocated 
to usual care and 325 to CRP-POCT. CRP-
POCT data were not available for eight 
participants, leaving 241 allocated to CRP-
POCT with a CRP value <20 mg/l, and 76 
allocated to CRP-POCT with a CRP value 
≥20 mg/l (Figure 1). See Supplementary 
Table S2 for details of descriptive statistics 
overall, by CRP measurement, and by 
antibiotic prescription receipt at the index 
consultation. 
Numbers analysed
One participant (CRP not measured) 
did not have data available regarding 
antibiotic prescribing decisions at the index 
consultation. Data availability varied for each 
of the candidate variables, and numbers of 
participants for each are given in Table 1. 
Antibiotics were prescribed at the index 
consultation to 225 (69.7%) participants in 
whom CRP was not measured, 79 (32.8%) 
with CRP <20 mg/l, and 68 (89.5%) with 
Figure 1. Participant flow diagram.  
CRP = C-reactive protein. PI = principal investigator. 
POCT = point-of-care test.
Randomised into the PACE study,
N = 653
Data available from the PACE study,
n = 649
Withdrew consent to use data, n = 3
Randomised in error and data destroyed by local PI, n = 1
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CRP ≥20 mg/l (see Supplementary Table S2 
for details).
Demographic features and comorbid 
illness
Higher participant age was associated 
with lower odds of antibiotic prescribing 
(adjusted odds ratio [AOR] per additional 
year increase = 0.98, 95% confidence 
interval [CI] = 0.95 to 1.00, P = 0.035) 
(Table 1). The presence of heart failure was 
associated with lower odds of antibiotic 
prescribing (AOR = 0.32, 95% CI = 0.12 to 
0.85, P = 0.022). There was no evidence 
that the association between any of the 
patient characteristics and antibiotics 
were different by CRP measurement (see 
Supplementary Table S3 for details).
Practice-level ICCs for demographic 
features and comorbid illness ranged from 
0.02 (95% CI = 0.00 to 0.17) for age to 0.13 
(95% CI = 0.05 to 0.28) for the presence 
of at least one comorbid illness (see 
Supplementary Figure S1 for details).
Symptoms and signs
Clinician-reported chest auscultation 
findings of crackles (AOR = 5.22, 95% 
CI = 3.24 to 8.41, P<0.001), wheeze 
(AOR = 1.64, 95% CI = 1.07 to 2.52, 
P = 0.022), and diminished vesicular 
breathing (AOR = 2.95, 95% CI = 1.70 to 
5.10, P<0.001), as well as clinician-reported 
evidence of consolidation (AOR = 34.40, 
95% CI = 2.84 to 417.27, P = 0.005), were 
all associated with higher odds of antibiotic 
prescribing (Table 1). A greater number of 
participants in the high CRP group (59.2%) 
experienced crackles than did those in the 
low CRP group (44.0%) (see Supplementary 
Table S2).
ICCs for clinical features ranged from 
0.02 (95% CI = 0.00 to 0.15) for pulse rate to 
0.60 (95% CI = 0.32 to 0.81) for evidence of 
consolidation on auscultation of the lungs 
(see Supplementary Figure S2 for details).
There was evidence to suggest a 
differential association between increased 
sputum volume and antibiotic prescribing 
by CRP measurement. Specifically, while an 
increase in sputum volume was associated 
with higher odds of antibiotic prescribing 
for participants in whom CRP was not 
measured (increased sputum volume 
main effect odds ratio [OR] = 2.18, 95% 
CI = 1.17 to 4.07; CRP <20 mg/l main 
effect = 0.30, 95% CI = 0.13 to 0.65; CRP 
≥20 mg/l main effect: 5.88, 95% CI = 1.36 
to 25.50) (see Supplementary Table S3 for 
details), there was minimal influence on 
antibiotic prescribing for those with CRP 
<20 mg/l (interaction between increased 
Table 1. Associations between demographic features, comorbid 
illness, symptoms and signs, and antibiotic prescribing at the index 
consultation
 Adjusted 
Variablea odds ratiob 95% CI P-value
Demographic features and  
comorbid illness   
Age, years (n = 640) 0.98 0.95 to 1.00 0.035
Sex (n = 640)  
 Male  Ref   
 Female 1.17 0.77 to 1.78 0.472
Heart failure (n = 640) 0.32 0.12 to 0.85 0.022
Chronic heart disease (n = 640) 0.89 0.52 to 1.51 0.657
Diabetes (n = 640) 1.43 0.81 to 2.50 0.215
Chronic kidney disease (n = 640) 1.76 0.81 to 3.81 0.151
Hypertension (n = 640) 1.02 0.66 to 1.56 0.934
Other chronic disease (n = 581) 0.80 0.48 to 1.32 0.379
At least one comorbid illness (n = 625) 0.85 0.53 to 1.34 0.479
Smoking status (n = 551)  
 Non-smoker Ref 
 Current smoker 1.14 0.45 to 2.88 0.777 
 Ex-smoker 1.08 0.45 to 2.59 0.867
COPD severity (n = 551)  
 GOLD stage 1 (mild) Ref   
 GOLD stage 2 (moderate) 1.52 0.83 to 2.81 0.179 
 GOLD stage 3 (severe) 1.62 0.81 to 3.27 0.176 
 GOLD stage 4 (very severe) 1.15 0.43 to 3.10 0.782
Symptoms and signs    
Days with symptoms (per day) (n = 640) 0.98 0.94 to 1.02 0.235
Increased breathlessness (n = 640) 1.72 0.86 to 3.41 0.124
Increased sputum volume (n = 640) 1.40 0.85 to 2.31 0.181
Sputum colour (n = 568)  
 1 (lightest) Ref   
 2 0.79 0.40 to 1.54 0.485 
 3 1.38 0.69 to 2.76 0.358 
 4 0.82 0.40 to 1.68 0.587 
 5 (darkest) 2.37 0.80 to 6.98 0.119
Crackles (n = 640) 5.22 3.24 to 8.41 <0.001
Wheeze (n = 640) 1.64 1.07 to 2.52 0.022
Diminished vesicular breathing (n = 638) 2.95 1.70 to 5.10 <0.001
Clinician-reported evidence  34.40 2.84 to 417.27 0.005 
of consolidation (n = 638)
Patient cannot complete a full sentence 1.30 0.46 to 3.66 0.623  
without stopping (n = 581)
Patient is tachypnoeic (n = 581) 1.30 0.70 to 2.43 0.405
Temperature (n = 639) 1.33 0.87 to 2.04 0.186
Pulse rate (n = 639) 1.01 0.99 to 1.03 0.250
Oxygen saturation (n = 637) 0.96 0.89 to 1.05 0.397
Patient has been prescribed antibiotics  
in the past 12 months (n = 597) 0.95 0.60 to 1.49 0.809
an-values indicate number of available data for each variable. bModel adjusts for C-reactive protein (CRP) 
measurement (CRP measurement not available, CRP <20 mg/l, and CRP ≥20 mg/l), the presence of sputum 
purulence, and the clustered nature of participants within practices. CI = confidence interval. COPD = chronic 
obstructive pulmonary disease. GOLD = Global Initiative for Chronic Obstructive Lung Disease.
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sputum volume and CRP <20 mg/l 
OR = 0.31, 95% CI = 0.12 to 0.80) (Figure 2). 
Evidence of consolidation was reported 
for 18 participants in total (seven in those 
for whom CRP was not measured, eight 
with CRP <20 mg/l, and three with CRP 
≥20 mg/l). All but one of these participants 
(who had CRP <20 mg/l) were prescribed 
antibiotics at the index consultation (data 
not shown). The reporting of crackles 
was associated with the highest odds of 
antibiotic prescribing, and there was no 




This study investigated antibiotic 
prescribing associations for patients with 
AECOPD in UK primary care. It found 
that lower age, presence of heart failure, 
and clinician-reported abnormal findings 
on examination of the lungs (crackles, 
wheeze, diminished vesicular breathing, 
and evidence of consolidation) were all 
associated with antibiotic prescribing at the 
index consultation after adjusting for CRP 
measurement category and the presence 
of increased purulent sputum.
Increased patient-reported sputum 
volume was associated with antibiotic 
prescribing when CRP was not measured, 
but considerably less so when it was 
measured. Reporting crackles on 
auscultation was the feature most strongly 
associated with antibiotic prescribing, and 
the magnitude of this association was large 
across all three CRP measurement groups.
Strengths and limitations
These data were obtained from the largest 
trial of patients with AECOPD in UK primary 
care, covering 86 general practices across 
England and Wales. The trial benefitted 
from a representative sample of this 
patient population,8,16 and, with high data 
completion, most participants were 
retained for these analyses. Clinicians in the 
participating practices were trained in study 
procedures and data collection processes 
in accordance with a standardised protocol, 
and this minimised any biases arising from 
variable research practices.
This was a secondary analysis of a 
randomised controlled trial, and no formal 
power calculation was conducted for these 
particular analyses. Furthermore, the ICC 
estimates should be interpreted with some 
caution, as these were obtained from data 
arising from a randomised controlled trial, 
and the sources of variation may reflect on 
the type of person a clinician was willing 
to include in such a trial. In addition, 
the calculation of ICC values on the log-
odds scale for binary variables, while not 
depending on cluster prevalence, may not 
directly translate to other studies. The ICC 
of 0.60 for clinician-reported evidence of 
consolidation likely reflects the variability in 
clinical assessment of this feature, as well 
as how rare it is in primary care. Finally, it 
is not possible to draw causal conclusions 
regarding the presenting features and their 
relationship to antibiotic prescribing. 
The considerable practice variation in 
recording of clinical features suggests a 
high degree of subjectivity, as has been 
shown in previous studies.17,18 It is also not 
possible to rule out a relationship between 
clinical features and antibiotic prescribing 
being confounded by clinicians’ perceptions 
of the need for antibiotics, which have 
previously been shown to influence the 
recording of ‘objective’ features such as 
clinical findings and diagnosis.19 
Comparison with existing literature
Several of the study’s findings are consistent 
with previous studies on the determinants 
of antibiotic prescribing for acute cough/
lower respiratory tract infection in primary 
care, including crackles, wheeze, and 
diminished breath sounds (and other 
abnormal auscultation findings).20–23 
The finding that increasing age was 
associated with lower odds of antibiotic 
prescribing was unexpected and inconsistent 
with the study by Llor and colleagues.4 
The current study differs in two key ways. 
First, it was a randomised controlled trial 
with several eligibility criteria, whereas 
Figure 2. Differential association between increased 
sputum volume and antibiotic prescribing by CRP 
measurement. Vertical lines indicate 95% CIs.  
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the study by Llor and colleagues was an 
observational study, in which clinicians 
included all patients over a defined time 
period. Thus, the current study may have 
inadvertently excluded older participants 
who would more likely be prescribed 
antibiotics, despite there being no upper 
age limit. Second, the association between 
age and antibiotic prescribing in the current 
study was adjusted for CRP measurement 
and increased sputum purulence (none, 
<20 mg/l, or ≥20 mg/l), whereas the study 
by Llor and colleagues was adjusted for 
several variables in a multivariable analysis 
(sex, days with symptoms, several different 
types of symptoms, utilisation of CRP, 
clinician request for a chest X-ray, and 
patient demanding antibiotics).
The weak association between sputum 
volume and antibiotic prescribing may 
indicate that clinicians are less certain about 
an increase in sputum volume as an indicator 
of bacterial infection compared with other 
clinical features. This is in line with the 
GOLD statement24 that sputum purulence is 
the strongest predictor of bacterial infection 
among the Anthonisen criteria, and that 
sputum volume and increased dyspnoea 
should not be emphasised in the absence of 
purulence. This point of view is supported by 
Miravitlles and colleagues,25 who found that 
purulence was the only Anthonisen criterion 
independently predicting an unfavourable 
outcome in patients with AECOPD treated 
with placebo. 
Implications for research 
Clinicians use a range of demographic 
and clinical features, including age and 
lung sounds, in their decision to prescribe 
antibiotics to patients presenting with 
AECOPD in UK primary care. In this study, 
the importance attributed to chest findings, 
and crackles in particular, in deciding on 
prescribing of antibiotics for AECOPD is 
not supported by a strong evidence base 
nor included in current guidelines. The 
emphasis on crackles by clinicians is 
probably related to the increased frequency 
found in pneumonia.26 However, crackles are 
commonly heard in COPD,27 and especially 
during exacerbations, related to worsened 
bronchial obstruction.28 In the present 
study, while the link between crackles and 
antibiotic prescribing was independent of 
CRP result, a greater number of participants 
in the high CRP group (59.2%) experienced 
crackles than did those in the low CRP 
group (44.0%), indicative of a relationship 
between crackles and more seriously 
unwell participants. Further investigation 
is required to determine the diagnostic 
and prognostic value of crackles and other 
chest sounds, and whether further safe 
reductions in antibiotic prescribing for 
AECOPD are possible.
Figure 3. Differential association between reporting 
crackles on auscultation and antibiotic prescribing by 
CRP measurement. Vertical lines indicate 95% CIs. 
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